

# NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

NCT05189925

---

Status	RECRUITING
Phase	Phase 1
Sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment	25 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Individuals must meet all of the following criteria to be eligible for study participation:
- Males aged 18 to 75 years
- CGD confirmed by DHR and deficiency subtype confirmed by protein analysis and/or genetic sequencing
- Has a physician at home for follow-up care
- Able to provide informed consent
- ... and 3 more (see full listing online)

### Exclusion (22)

- Individuals meeting any of the following criteria will be excluded from study participation:
- Clinically unstable due to moderate to severe acute systemic infections as defined by persistent resting tachypnea, tachycardia, or hypoxia of  $>20\%$  from baseline and hypotension.
- Current or history of stage 4 chronic kidney disease or estimated glomerular filtration rate  $[eGFR] <30$  mL/min/1.73 m<sup>2</sup> within 90 days of baseline.
- Unstable diabetes mellitus with hemoglobin A1c  $>7.0\%$  and fasting serum glucose  $>200$  mg/dL at screening.
- Current or history of heart failure stage D as defined by the American College of Cardiology Foundation/American Heart Association guidelines.
- ... and 17 more (see full listing online)

## Locations (1 total)

---

National Institutes of Health Clinical Center, Bethesda, Maryland, United States